AMBU FINANCIAL CALENDAR FOR 2023/24

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as the date of Ambu’s Annual General Meeting. 

2023

8 NOVEMBER 2023 Annual Report 2022/23
13 DECEMBER 2023 Annual General Meeting 2023


2024

30 JANUARY 2024 Earnings release Q1 2023/24
14 MAY 2024 Earnings release Q2 2023/24
30 AUGUST 2024 Earnings release Q3 2023/24
30 SEPTEMBER 2024 End of fiscal year 2023/24
5 NOVEMBER 2024 Annual Report 2023/24
4 DECEMBER 2024 Annual General Meeting 2024

The deadline for the inclusion of specific items on the agenda for the Annual General Meeting 2023 is 31 October 2023.

Ambu A/S
Baltorpbakken 13
2750 Ballerup
Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.Ambu.com


CONTACT INFORMATION

Media
Tine Bjørn Schmidt
Head of Corporate Communications
tisc@ambu.com
+45 2264 0697

Investors
Anders Hjort
Head of Investor Relations
anhj@ambu.com
+45 2892 8881


ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.

Attachment

Staff

Recent Posts

Mobile-health Network Solutions Announces Share Repurchase Program of up to 214,000 Shares

Singapore, Singapore--(Newsfile Corp. - June 5, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or…

2 hours ago

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a…

2 hours ago

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

Dr. Lessieur-Contreras will continue her groundbreaking research on understanding the early stages of diabetic retinopathy…

2 hours ago

Precision Optics Expands Facilities to Meet Growing Backlog

Company signs lease to move corporate offices and engineering development to Littleton, MA Move allows…

2 hours ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a…

2 hours ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009…

2 hours ago